Cargando…

Salivary cortisol in women with major depressive disorder under selective serotonin reuptake inhibitors therapy

Depression is one of the widespread diseases whose etiology is still unclear. Dysregulation of the hypothalamic–pituitary–adrenal axis can be the cause of this illness which is concomitant with a high level of cortisol. For this reason, the purpose of the study was to estimate the influence of the s...

Descripción completa

Detalles Bibliográficos
Autores principales: Dziurkowska, Ewelina, Wesolowski, Marek, Dziurkowski, Maciej
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Vienna 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3594819/
https://www.ncbi.nlm.nih.gov/pubmed/23371518
http://dx.doi.org/10.1007/s00737-013-0329-z
_version_ 1782262350384988160
author Dziurkowska, Ewelina
Wesolowski, Marek
Dziurkowski, Maciej
author_facet Dziurkowska, Ewelina
Wesolowski, Marek
Dziurkowski, Maciej
author_sort Dziurkowska, Ewelina
collection PubMed
description Depression is one of the widespread diseases whose etiology is still unclear. Dysregulation of the hypothalamic–pituitary–adrenal axis can be the cause of this illness which is concomitant with a high level of cortisol. For this reason, the purpose of the study was to estimate the influence of the selective serotonin reuptake inhibitors (SSRIs) therapy used in monotherapy and polypragmasy on cortisol level in saliva of depressed women. Cortisol was determined in saliva collected from 40 depressed patients treated with SSRIs. HPLC with UV detection was used for quantification of cortisol after its extraction with dichloromethane. For statistical evaluation of the data, the cluster analysis and principal components analysis were used. Results of the study have shown that the SSRIs treatment reduces the cortisol level in saliva. The therapy with sertraline and polypragmasy had a strong influence on suppressing the cortisol secretion. Besides, the amplitude of changes of the cortisol level during the treatment had an impact on the duration of hospitalization. In conclusion, it can be stet that the process of reduction of the cortisol level is multiphasic and that the combination treatment had a stronger influence on suppressing the cortisol secretion than did antidepressants used in monotherapy.
format Online
Article
Text
id pubmed-3594819
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Springer Vienna
record_format MEDLINE/PubMed
spelling pubmed-35948192013-03-14 Salivary cortisol in women with major depressive disorder under selective serotonin reuptake inhibitors therapy Dziurkowska, Ewelina Wesolowski, Marek Dziurkowski, Maciej Arch Womens Ment Health Original Article Depression is one of the widespread diseases whose etiology is still unclear. Dysregulation of the hypothalamic–pituitary–adrenal axis can be the cause of this illness which is concomitant with a high level of cortisol. For this reason, the purpose of the study was to estimate the influence of the selective serotonin reuptake inhibitors (SSRIs) therapy used in monotherapy and polypragmasy on cortisol level in saliva of depressed women. Cortisol was determined in saliva collected from 40 depressed patients treated with SSRIs. HPLC with UV detection was used for quantification of cortisol after its extraction with dichloromethane. For statistical evaluation of the data, the cluster analysis and principal components analysis were used. Results of the study have shown that the SSRIs treatment reduces the cortisol level in saliva. The therapy with sertraline and polypragmasy had a strong influence on suppressing the cortisol secretion. Besides, the amplitude of changes of the cortisol level during the treatment had an impact on the duration of hospitalization. In conclusion, it can be stet that the process of reduction of the cortisol level is multiphasic and that the combination treatment had a stronger influence on suppressing the cortisol secretion than did antidepressants used in monotherapy. Springer Vienna 2013-01-31 2013 /pmc/articles/PMC3594819/ /pubmed/23371518 http://dx.doi.org/10.1007/s00737-013-0329-z Text en © The Author(s) 2013 https://creativecommons.org/licenses/by-nc/2.0/ Open Access This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.
spellingShingle Original Article
Dziurkowska, Ewelina
Wesolowski, Marek
Dziurkowski, Maciej
Salivary cortisol in women with major depressive disorder under selective serotonin reuptake inhibitors therapy
title Salivary cortisol in women with major depressive disorder under selective serotonin reuptake inhibitors therapy
title_full Salivary cortisol in women with major depressive disorder under selective serotonin reuptake inhibitors therapy
title_fullStr Salivary cortisol in women with major depressive disorder under selective serotonin reuptake inhibitors therapy
title_full_unstemmed Salivary cortisol in women with major depressive disorder under selective serotonin reuptake inhibitors therapy
title_short Salivary cortisol in women with major depressive disorder under selective serotonin reuptake inhibitors therapy
title_sort salivary cortisol in women with major depressive disorder under selective serotonin reuptake inhibitors therapy
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3594819/
https://www.ncbi.nlm.nih.gov/pubmed/23371518
http://dx.doi.org/10.1007/s00737-013-0329-z
work_keys_str_mv AT dziurkowskaewelina salivarycortisolinwomenwithmajordepressivedisorderunderselectiveserotoninreuptakeinhibitorstherapy
AT wesolowskimarek salivarycortisolinwomenwithmajordepressivedisorderunderselectiveserotoninreuptakeinhibitorstherapy
AT dziurkowskimaciej salivarycortisolinwomenwithmajordepressivedisorderunderselectiveserotoninreuptakeinhibitorstherapy